Trials / Completed
CompletedNCT00950950
A Study to Evaluate the Effect of Romosozumab (AMG 785) on Bone Quality of the Forearm in Postmenopausal Women With Low Bone Mass
A Randomized, Double-blind, Placebo-controlled, Multiple Dose Study to Evaluate the Effect of AMG 785 on Parameters of Bone Quality of the Forearm Using pQCT in Postmenopausal Women With Low Bone Mineral Density
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Amgen · Industry
- Sex
- Female
- Age
- 55 Years – 80 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the effect of romosozumab on parameters of bone quality of the forearm using peripheral quantitative computed tomography (pQCT) following multiple subcutaneous dose administrations of romosozumab in postmenopausal women with low bone mass.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Romosozumab | Administered by subcutaneous injection |
| DRUG | Placebo | Administered by subcutaneous injection |
Timeline
- Start date
- 2009-08-18
- Primary completion
- 2010-08-19
- Completion
- 2010-08-19
- First posted
- 2009-08-03
- Last updated
- 2019-07-05
- Results posted
- 2019-07-05
Source: ClinicalTrials.gov record NCT00950950. Inclusion in this directory is not an endorsement.